Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.36 USD
Change Today -0.10 / -0.30%
Volume 68.6K
OFIX On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

orthofix international nv (OFIX) Snapshot

Open
$33.49
Previous Close
$33.46
Day High
$33.82
Day Low
$33.26
52 Week High
04/2/15 - $38.94
52 Week Low
10/16/14 - $26.96
Market Cap
626.0M
Average Volume 10 Days
106.0K
EPS TTM
$-0.16
Shares Outstanding
18.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ORTHOFIX INTERNATIONAL NV (OFIX)

orthofix international nv (OFIX) Related Businessweek News

No Related Businessweek News Found

orthofix international nv (OFIX) Details

Orthofix International N.V., a medical device company, provides reconstructive and regenerative orthopedic and spine solutions to physicians. It operates through four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The BioStim segment manufactures, distributes, and provides support services for a range of devices that enhance bone fusion and are indicated as treatment to improve fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The company markets and distributes its products through independent distributors, independent sales representatives, and affiliates, as well as directly in the United States, Italy, the United Kingdom, Germany, Switzerland, Austria, France, Brazil, Australia, and Puerto Rico. It serves hospitals, doctors, and other healthcare providers. The company was founded in 1987 and is headquartered in Willemstad, Curaçao.

922 Employees
Last Reported Date: 04/29/15
Founded in 1987

orthofix international nv (OFIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $610.8K
Chief Financial Officer and Chief Accounting ...
Total Annual Compensation: $138.3K
President of Global Extremity Fixation
Total Annual Compensation: $555.3K
Chief Strategy Officer
Total Annual Compensation: $630.9K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $631.8K
Compensation as of Fiscal Year 2014.

orthofix international nv (OFIX) Key Developments

Orthofix Announces the Addition of Lilly Marks to Board of Directors

Orthofix International N.V. announced that it has named Lilly Marks to its Board of Directors. she serves as the Vice President for Health Affairs for the University of Colorado and has led the University of Colorado Anschutz Medical Campus, which includes the schools of medicine, pharmacy, dentistry, nursing, public health and the graduate school.

Orthofix International N.V. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM

Orthofix International N.V. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Orthofix International N.V. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Year 2015

Orthofix International N.V. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales were $89.8 million, a 10.3% decline compared to $100.0 million in the prior year period. Net sales decreased by 7.4% on a constant currency basis. Operating loss was $7.2 million compared to $0.0 million in first quarter of 2014. Adjusted EBITDA from continuing operations, which excluded share-based compensation, foreign exchange impact, interest income, strategic investments, accounting review and restatement expenses, Bluecore infrastructure investments and a gain on the sale of assets was $8.4 million or 9.4% of net sales, compared to $14.9 million or 14.9% of net sales in the prior year period. Net loss from continuing operations was $7.7 million, or $0.41 per basic and diluted share, compared to $1.9 million, or $0.11 per basic and diluted share in the prior year period. Adjusted net loss from continuing operations was $2.8 million, or $0.15 per basic and diluted share, compared to adjusted net income of $3.2 million, or $0.18 per basic and diluted share in first quarter of 2014. Loss before income taxes was $6.773 million against $0.769 million a year ago. Net loss was $8.379 million or $0.45 per basic and diluted share against $2.508 million or $0.14 per basic and diluted share a year ago. LBITDA was $1.193 million against EBITDA of $5.302 million a year ago. Adjusted EBITDA was $8.424 million against $14.858 million a year ago. The decline was due to the decrease in net sales and the increase in SG&A expenses supporting strategic initiatives. Net cash provided by operating activities was $4.941 million against net cash used by operating activities of $10.212 million a year ago. Capital expenditures were $5.113 million against $3.737 million a year ago. The increase in operating cash flow is primarily reflective of the year-over-year increase in cash provided by working capital accounts, specifically changes in accounts receivable and accounts payable. The company expects capital expenditures to be between $20 million and $25 million for the full year 2015, which includes Bluecore investments and expects full year 2015 effective tax rate, varying any unanticipated discrete items, to e between 40% and 50%, but the rate may vary widely on a quarterly basis. The company expects to report net sales in the range of $385 million to $390 million, based on current exchange rates. This would represent flat year-over-year growth at the midpoint of its range at constant currency. Additionally, the company expects adjusted EBITDA to be in the range of $55 million to $58 million in 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OFIX:US $33.36 USD -0.10

OFIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $15.50 USD +0.29
Exactech Inc $19.98 USD +0.18
NxStage Medical Inc $14.28 USD +0.29
RTI Surgical Inc $7.28 USD +0.47
Tornier NV $24.89 USD -0.10
View Industry Companies
 

Industry Analysis

OFIX

Industry Average

Valuation OFIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORTHOFIX INTERNATIONAL NV, please visit www.orthofix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.